COVID-19 vaccines and kidney disease

Martin Windpessl; Annette Bruchfeld; Hans-Joachim Anders; Holly Kramer; Meryl Waldman; Laurent Renia; Lisa F P Ng; Zhou Xing; Andreas Kronbichler

doi:10.1038/s41581-021-00406-6

COVID-19 vaccines and kidney disease

Nat Rev Nephrol. 2021 May;17(5):291-293. doi: 10.1038/s41581-021-00406-6. Epub 2021 Feb 8.

Authors

Martin Windpessl^#^{1

2}, Annette Bruchfeld^#^{3

4}, Hans-Joachim Anders^#⁵, Holly Kramer^{6

7}, Meryl Waldman⁸, Laurent Renia^{9

10}, Lisa F P Ng^{9

10

11

12}, Zhou Xing^{13

14

15}, Andreas Kronbichler^{16

17}

Affiliations

¹ Department of Internal Medicine IV, Section of Nephrology, Klinikum Wels-Grieskirchen, Wels, Austria.
² Medical Faculty, Johannes Kepler University, Linz, Austria.
³ Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden.
⁴ Department of Renal Medicine, Karolinska University Hospital and CLINTEC Karolinska Institutet, Stockholm, Sweden.
⁵ Division of Nephrology, Medizinische Klinik und Poliklinik IV, LMU Klinikum, Munich, Germany.
⁶ Department of Public Health Sciences and Medicine, Loyola University Chicago Stritch School of Medicine, Maywood, IL, USA.
⁷ Hines VA Medical Center, Hines, IL, USA.
⁸ Kidney Disease Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Health, Bethesda, MD, USA.
⁹ A*STAR Infectious Diseases Labs, Agency for Science, Technology and Research, Singapore, Singapore.
¹⁰ Singapore Immunology Network, Agency for Science, Technology and Research, Singapore, Singapore.
¹¹ Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
¹² Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK.
¹³ McMaster Immunology Research Centre, McMaster University, Hamilton, ON, Canada.
¹⁴ Department of Medicine, McMaster University, Hamilton, ON, Canada.
¹⁵ Michael G. DeGroote Institute for Infectious Disease Research, McMaster University, Hamilton, ON, Canada.
¹⁶ Department of Medicine, University of Cambridge, Cambridge, UK. [email protected].
¹⁷ Department of Internal Medicine IV, Nephrology and Hypertension, Medical University Innsbruck, Innsbruck, Austria. [email protected].

^# Contributed equally.

Abstract

Patients with kidney diseases should be prioritized for COVID-19 vaccination and the available data suggest that replication-defective viral-vectored vaccines and mRNA vaccines are safe to use. As vaccine responses are likely to be lower in patients with kidney diseases than in the general population, highly potent vaccines should be preferred.

Publication types

Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't

MeSH terms

COVID-19 / prevention & control*
COVID-19 Vaccines / immunology*
Humans
Immunosuppression Therapy
Kidney Diseases / complications
Kidney Diseases / immunology*
Renal Dialysis
SARS-CoV-2 / immunology*
Vaccination

Substances

COVID-19 Vaccines

Grants and funding

DK/NIDDK NIH HHS/United States